Skip to main content

Building biotech companies and raising venture capital financing: Pureos Bioventures, Alentis and Engimmune (EN)

BaseLaunch invites you to this biotech networking event on Tuesday, 27th September 2022, empowered by Innosuisse featuring Pureos Biovetures, Alentis Therapeutics and Engimmune Therpaueutics.

Launching and financing a biotech company is a challenging endeavor with many things to get right from the beginning. Besides the science side requiring heavy de-risking, the business aspects like building a team, licensing the IP, strategic decisions concerning the pipeline and lead indications as well as the business plans require attention too.

All of this requires the scientific founders to leave their comfort zone but is crucial to build the foundation for the initial financing and future growth of the company.

This event will feature two successful scientific founders, who will share their stories: Prof. Thomas Baumert from Alentis Therapeutics which raised over CHF $80M in venture capital and Dr. Rodrigo Vazquez-Lombardi from Engimmune Therapeutics who closed a seed financing of $16.7M this year. In addition, we are very proud that Dominik Escher from Pureos Bioventures – one of our BaseLaunch partners and early investor in both companies – is joining us to share his perspective on partnering with early-stage founders.



Door opening


Stephan Emmerth, BaseLaunch


Pureos Bioventures
Dominik Escher


Alentis Therapeutics
Thomas Baumert


Engimmune Therapeutics
Rodrigo Vazquez-Lombardi


Q & A
with all speakers


Networking Apéro

Participation is free, however registration is required before September 20th, 2022.

Our partners